Please Wait
Applying Filters...
menu
    • menu
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Veranova: A CDMO that manages complexity with confidence.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    An Enquiry

    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Exatecan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Innate Pharma Unveils 2025 Financials And Business Update
    Innate Pharma Unveils 2025 Financials And Business Update

    26 Mar 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-03-26/innate-pharma-reports-full-year-2025-financial-results-and-business-update

    PHARMIWEB
    26 Mar 2026
    Share Share
    Avacta Presents Pre|Cision Candidates At 2026 AACR Conference
    Avacta Presents Pre|Cision Candidates At 2026 AACR Conference

    17 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/17/3256882/0/en/Avacta-Announces-Preclinical-and-Translational-Presentations-of-pre-CISION-Platform-Candidates-at-the-2026-AACR-Annual-Conference.html

    GLOBENEWSWIRE
    17 Mar 2026
    Share Share
    FDA Clears Avacta's IND Application for AVA6103 (FAP-Exatecan)
    FDA Clears Avacta's IND Application for AVA6103 (FAP-Exatecan)

    21 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/21/3222755/0/en/Avacta-Announces-U-S-Food-and-Drug-Administration-Clearance-of-the-Investigational-New-Drug-IND-Application-for-the-Second-pre-CISION-Medicine-FAP-Exatecan-AVA6103.html

    GLOBENEWSWIRE
    21 Jan 2026
    Share Share
    FDA Grants Breakthrough Designation to Lilly's Sofetabart
    FDA Grants Breakthrough Designation to Lilly's Sofetabart

    20 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/lillys-sofetabart-mipitecan-receives-us-fdas-breakthrough-therapy-designation-for-the-treatment-of-certain-patients-with-platinum-resistant-ovarian-cancer-302665319.html

    PR NEWSWIRE
    20 Jan 2026
    Share Share
    Sutro Bio Doses First Patients In STRO-004, Phase 1 Trial
    Sutro Bio Doses First Patients In STRO-004, Phase 1 Trial

    03 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/03/3198799/0/en/Sutro-Biopharma-Announces-First-Cohort-of-Patients-Dosed-in-Phase-1-Trial-of-STRO-004-a-Next-Generation-Tissue-Factor-ADC-in-TF-Expressing-Solid-Tumors.html

    GLOBENEWSWIRE
    03 Dec 2025
    Share Share
    Kivu Bioscience Shows Strong Anti-Tumor Activity Of KIVU-107
    Kivu Bioscience Shows Strong Anti-Tumor Activity Of KIVU-107

    20 Oct 2025

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2025-10-20/kivu-bioscience-presents-preclinical-data-for-kivu-107-demonstrating-potent-and-durable-anti-tumor-a

    PHARMIWEB
    20 Oct 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.